Name: Painchek (PCK) Short Position History
Creator: Shorted
License: https://creativecommons.org/licenses/by/4.0/

PCK

Health Care Equipment & Services

Painchek

Short interest: 0.00%; 0.00 pp 30d; as of 21 May 2026
Reported shorts: 1.5K
Shares on issue: 209.007M

Price & short interest

Toggle series, zoom, and compare · ASIC daily, T+4

About Painchek

Painchek is focused on developing and commercializing mobile medical applications for pain assessment, particularly for individuals with communication difficulties. Their core product, PainChek®, is a regulatory-cleared medical device that uses AI to assess pain through facial analysis and other indicators. The company aims to improve pain management and medication treatment for vulnerable populations in aged care and other settings.

Company profile →

Painchek (ASX:PCK) has 0.00% of its shares on issue reported as short positions as of 21 May 2026, or about 1,469 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. Its highest recorded short interest was 0.37% in October 2020. PCK is classified in the Health Care Equipment & Services industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.

Short interest

History & FAQ →

Weekly context: The 10 most shorted ASX stocks — Week 41, 2026.

Strategy fit

How each stock picker strategy reads PCK today

Zanger BreakoutNot a candidate
CAN SLIMNot a candidate
Minervini Trend TemplateNot a candidate
Crowded-Short BreakoutNot a candidate
Quality compoundersWatchScore 8rank 1425 of 1669

Prices to 14 Oct 2026 · Mechanical readings of published rules, not recommendations · Not financial adviceFull strategy readings →

PCK fundamentals

In the year to 30 Jun 2026, Painchek (ASX:PCK) recorded revenue of A$3.8M and a net loss after tax of A$8.9M. A year earlier it recorded revenue of A$3.4M and a net loss after tax of A$7.7M. Year-on-year growth: revenue +12.0% (FY). Net margin −237.2% (FY). Figures are in AUD, the company's reporting currency; source: ASX (Markit), as at 14 Oct 2026.

Full statements, ratios and filings are on the Financials tab. Not financial advice.

Full financials →